Drug Profile
RV 568
Alternative Names: JNJ 49095397; RV-568Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator RespiVert
- Developer Janssen Biotech; RespiVert
- Class Antiasthmatics; Antibronchitics; Antihistamines; Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Lung disorders; Seasonal allergic rhinitis
Most Recent Events
- 22 Jul 2015 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation,Aerosol)
- 01 Sep 2014 Janssen Research & Development completes a phase II trial for Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (inhalation) (NCT01867762)
- 01 Sep 2013 Phase-II clinical trials in Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (Inhalation) after September 2013